Bochtler T et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol 2015;33(12):1371-8. Abstract

Cohen AD et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood 2016;128(22):645. Abstract

Comenzo RL et al. Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: Results from Andromeda. ASH 2020;Abstract 552.

Dispenzieri A et al. Primary results from the phase 3 Tourmaline-AL1 trial of ixazomib-dexamethasone versus physician’s choice of therapy in patients (pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL). ASH 2019;Abstract 139.

Palladini G et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015;126(5):612-5. Abstract

Sanchorawala V et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood 2017;130(5):597-605. Abstract

Sidiqi MH et al. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J 2020;10(5):55. Abstract